Amoy Diagnostics Co., Ltd. (300685)

Overview

Amoy Diagnostics Co., Ltd. is a pioneering diagnostic company primarily specializing in oncology, serving the market both within China and internationally. Its core focus lies in the development and commercialization of diagnostic products that enable more effective treatment pathways for cancer patients. Since its establishment in 2008 and with its base in Xiamen, China, Amoy Diagnostics has been at the forefront of creating innovative diagnostic solutions, contributing significantly to the advancements in targeted cancer treatment research.

Products and Services

• AmoyDx HRD Focus and Complete Panels: These panels are designed for the evaluation of PARP inhibitor-related biomarkers, particularly beneficial for ovarian cancer research. The HRD focus panel targets evaluating Homologous Recombination Deficiency (HRD), whereas the complete panel encompasses a wide detection range across HRR genes and HRD status.
• AmoyDx Master Panel: A comprehensive CGP assay intended for wide-ranging molecular testing in cancer diagnosis and treatment.
• AmoyDx BRCA Pro Panel: Offers a thorough examination of the BRCA1 and BRCA2 genes, covering protein-coding regions, intron/exon boundaries, select introns, and UTR regions, crucial for breast and ovarian cancer patient care.
• AmoyDx Classic and Essential NGS Panels: The Handle Classic NGS Panel detects multiple gene mutations for tailored cancer treatment, while the Essential NGS Panel specializes in genes associated with non-small cell lung cancer and colorectal cancer.
• AmoyDx HRR NGS Panel: Targets the detection of somatic and germline variants, further enhancing the precision in cancer diagnostics and treatment planning.
• AmoyDx Pan Lung Cancer PCR Panel: A tissue-based real-time qPCR assay designed for in vitro diagnostics, significantly impacting lung cancer detection and therapy.
• AmoyDx Myeloid Blood Cancer Panel: Specifically designed to tackle the complexities of diagnosing myeloid blood cancers through advanced genetic testing.
• AmoyDx Comprehensive Panel: A sequencing-based test capable of detecting a broad range of alterations, offering an extensive diagnosis capability for various cancers.
• AmoyDx PD-L1 (E1L3N) Assay: Facilitates the assessment of PD-L1 expression levels, a critical marker in cancer immunotherapy treatments.
• AmoyDx Melanoma NGS Panel: Developed for detecting significant mutations within pivotal melanoma tumor genes, aiding in the customized treatment of melanoma.
• Additional Diagnostic Kits: Amoy Diagnostics provides an extensive range of detection kits, including those for ALK and ROS1 gene fusions, EML4-ALK, EGFR/ALK/ROS1 mutations, MET, HER2, RET fusions, KRAS, BRAF, PIK3CA mutations, microsatellite instability, human papillomavirus genotyping, JAK2, TERT/HRAS, NTRK gene fusions, and BRAF V600 mutations, under the Super-ARMS and AmoyDx brand names.
• DNA and RNA Extraction Kits: Essential tools for molecular testing, allowing for the extraction of high-quality nucleic acids from samples, critical for accurate diagnostic testing.